{"slug":"peg-mgf","seoKey":"pegmgf","displayName":"PEG-MGF","codes":[],"synonyms":["PEG MGF","Pegylated mechano growth factor","Pegylated MGF","Mechano Growth Factor, Pegylated","PEG-IGF-1Ec"],"legalClass":"research_chemical","identifiers":{},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and never submitted: the approvals, labelling and enforcement endpoints each returned no record for the substance or for mechano growth factor on 2026-09-16, while a control query for mecasermin returned records on the same endpoints, so the negative finding is verified. There is no product labelling, no recall and no marketing registration. Two regulatory entries do exist and neither is an authorisation. The nomination list for bulk substances for compounding under section 503A, in the version updated 2026-05-14, carries 'Mechano growth factor (MGF)' in category 3, nominated without adequate support; a full-text search of that document for 'pegylat', 'PEG-' and 'polyethylene' returned no match anywhere, so the pegylated name is not on that list. Separately, the compounding advisory committee is due to meet before the end of February 2027 and to discuss 'Mechano Growth Factor, Pegylated (PEG-MGF)' for possible inclusion on the same list. That announcement is the only regulatory document found anywhere that uses the name. A committee discussion is neither a listing nor an approval. No warning letter naming either substance was found; the full-text search was limited, so that is a negative finding rather than a clearance.","source":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"},{"market":"EU","status":"not_approved","note":"No authorised medicine, no assessment report, no orphan designation and no withdrawn application. IMPORTANT CAVEAT: the regulator's search portal could not be queried by machine on 2026-09-16, answering with access errors, so this entry is inferred from the worldwide absence of any authorisation, any trial and any substance record rather than from a register match. The related molecule that does exist in development terms is a different one: a site-specifically pegylated recombinant human insulin-like growth factor I, pegylated at lysine 68, which has a published first-in-man study. That is not this substance.","source":"https://www.ema.europa.eu/en/medicines"},{"market":"DE","status":"not_approved","note":"Not an authorised medicine: there is neither a central European authorisation nor a national finished product, so every injectable preparation sold under the name is an unauthorised medicinal product. At the same time the substance group is named directly in criminal law. The annex to section 2(3) of the anti-doping act lists 'Mechano Growth Factor (MGF) und MGF-Varianten' in section II.3, alongside mecasermin, insulin-like growth factor 1 analogues and thymosin beta-4, and its closing clause extends the list to salts, esters, ethers, isomers, mixtures of isomers, complexes and derivatives. A pegylated conjugate of the peptide falls under that wording, which is why the name itself need not appear. The accompanying quantity regulation sets the threshold at which acquisition, possession, trade and manufacture for doping purposes become punishable at 3 mg for mechano growth factor and its variants, against 60 mg for mecasermin.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No authorised medicine and no product record. IMPORTANT CAVEAT: the regulator's product database serves its results by script and its interface endpoints answered with an error on 2026-09-16, so this entry rests on the worldwide absence of any authorisation rather than on a register extract. Unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012.","source":"https://products.mhra.gov.uk/"},{"market":"AU","status":"scheduled","note":"The strictest classification of any market checked, and it is a derivation rather than a direct listing. The poisons standard does not name this substance. It places 'INSULIN-LIKE GROWTH FACTOR I.' and 'INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule' in schedule 4, both marked as also carrying an appendix D entry, and the substance index records 'Schedule 4 / Appendix D, Item 5' against the class. Paragraph 3.5(1)(b) of the standard reads that a person must not knowingly have in his or her possession a poison listed in appendix D paragraph 5 without authority, so possession and not only supply is restricted. Mechano growth factor is the E-domain of a splice variant of insulin-like growth factor 1 and is therefore captured by the class term; a pegylated conjugate of it is not separately specified. Import is separately restricted: schedule 7A item 3 of the customs prohibited-imports regulations covers natural and manufactured growth hormones including insulin-like growth factors, and a freedom-of-information release document names PEG MGF under that item, although that document could not be retrieved directly and its wording is reported from a search index rather than verified. No registered finished product exists. Dated entry omitted deliberately: only the February 2020 compilation of the instrument was machine-readable, and a newer compilation could not be retrieved.","source":"https://www.legislation.gov.au/F2020L00017/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned an empty result on 2026-09-16 for both the pegylated name and 'MECHANO GROWTH FACTOR'. A control query for mecasermin returned a record on the same endpoint, so the interface was working and the negative finding is verified.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=MECHANO%20GROWTH%20FACTOR"},{"market":"CH","status":"not_approved","note":"No authorisation found on 2026-09-16. Context from a primary source rather than a register match: a joint study by the national anti-doping agency and a German doping-control centre analysed 1,190 doping products seized at the Swiss border, of which 146 were labelled as peptide hormones or growth factors. Fewer than a fifth of all products contained the stated substance in the stated amount, and the authors describe the pharmaceutical quality as substandard. That study does not name this substance but covers exactly this product category.","source":"https://www.swissmedic.ch/swissmedic/en/home.html"}],"devStage":"preclinical","strongestEvidence":"none","wada":{"status":"prohibited","section":"S2.3","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":[],"lastVerified":"2026-09-16","version":"1.0","published":true,"locale":"en","title":"PEG-MGF: what the evidence shows, status and safety","summary":"PEG-MGF is sold as a longer-acting mechano growth factor, but no published study has ever made, measured or tested such a molecule. The one peer-reviewed paper naming it is a 2026 review, which places it in its lowest evidence tier. Every published analysis of seized MGF material found an unpegylated variant instead. It is prohibited in sport and approved nowhere.","updated":"2026-09-16","url":"https://mypep.app/peptides/peg-mgf"}